Biotech - Spark Newswire

2 minute read

Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD

Today, 9:14 AM

Ocular Therapeutix Inc (NASDAQ:OCUL) announced interim 10-month data from its U.S. Phase 1 trial of OTX-TKI, axitinib intravitreal hydrogel implant for…

OCUL

1 minute read

Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients

By Vandana Singh

Today, 9:14 AM

Bristol-Myers Squibb & Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) announced the first publication and presentation of results from the KarMMa-3 Phase 3 study…

BMY

1 minute read

Siga Shares Move Lower; Traders Circulate medRXiv Link Titled ‘Poor evidence for an effect of tecovirimat in shortening recovery time in hospitalized mpox cases from real-world data’

By Benzinga Newsdesk

Today, 9:14 AM

https://www.medrxiv.org/content/10.1101/2023.02.07.23285617v1

SIGA

1 minute read

FDA
News

Bristol-Myers Squibb Highlights Abecma Data; Says Reduced Risk Of Disease Progression Or Death By 51% Vs Standard Regimens In Earlier Lines Of Therapy

By Benzinga Newsdesk

Today, 9:14 AM

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3

BMY

1 minute read

Evolus Not Affected By Recent Korean Court Ruling; Ruling By The Seoul Central District Court Does Not Affect Evolus’ Ability To Have Jeuveau Or Nuceiva Manufactured And Exported By Daewoong Or To Sell The Products In Any Of Its Markets

By Happy Mohamed

Today, 9:14 AM

No Effect on Manufacture, Export, Supply or Sale of Jeuveau® or Nuceiva® Settlement Agreement with Medytox Provided for Continued Manufacturing and Commercialization for Evolus Regardless of Any

EOLS

1 minute read

New Data Shows Roche’s Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder

By Vandana Singh

Today, 9:14 AM

Roche Holdings AG (OTC:RHHBY) announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab) in macular…

REGN

1 minute read

Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce

By Vandana Singh

Today, 9:14 AM

Eliem Therapeutics Inc (NASDAQ:ELYM) announced reprioritizing its pipeline to focus on its high potential preclinical Kv7.2/3 program (Kv7 Program) and the…

ELYM

2 minute read

Seelos Therapeutics To Present A Poster On SLS-004 At The 11th Annual Alzheimer’s & Parkinson’s Drug Development Summit February 21-23, 2023

By Happy Mohamed

Today, 9:14 AM

- Seelos recently released in vivo gene therapy data of SLS-004 utilizing CRISPR-dCas9 in Parkinson's disease demonstrating downregulation of alpha synuclein and recovery of tyrosine hydroxylase-positive (TH+)

SEEL

1 minute read

Independent Data Monitoring Committee Completed Its Prespecified Review Of Interim Safety Data In Phio Pharmaceuticals’s Phase 1B Trial Of Ph-762 For Advanced Melanoma, Recommending The Study To Continue Without Modification.

By Benzinga Newsdesk

Today, 9:14 AM

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T

PHIO

1 minute read

Novo Nordisk’s Partner Heartseed Has Dosed The First Patient In Phase 1/2 Study (LAPiS Study) With HS-001, An Investigational Cell Therapy For Heart Failure

By Benzinga Newsdesk

Today, 9:14 AM

An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure, and has given approval for the study to continue

NVO